Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease : a systematic review of clinical benefit. / Ulrik, Charlotte Suppli.

In: International Journal of Chronic Obstructive Pulmonary Disease, Vol. 7, 2012, p. 673-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ulrik, CS 2012, 'Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit', International Journal of Chronic Obstructive Pulmonary Disease, vol. 7, pp. 673-8. https://doi.org/10.2147/COPD.S35990

APA

Ulrik, C. S. (2012). Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. International Journal of Chronic Obstructive Pulmonary Disease, 7, 673-8. https://doi.org/10.2147/COPD.S35990

Vancouver

Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. International Journal of Chronic Obstructive Pulmonary Disease. 2012;7:673-8. https://doi.org/10.2147/COPD.S35990

Author

Ulrik, Charlotte Suppli. / Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease : a systematic review of clinical benefit. In: International Journal of Chronic Obstructive Pulmonary Disease. 2012 ; Vol. 7. pp. 673-8.

Bibtex

@article{3f2bf1bff0e6451d99b0687f96bab1b9,
title = "Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit",
abstract = "Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD.",
author = "Ulrik, {Charlotte Suppli}",
year = "2012",
doi = "10.2147/COPD.S35990",
language = "English",
volume = "7",
pages = "673--8",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease

T2 - a systematic review of clinical benefit

AU - Ulrik, Charlotte Suppli

PY - 2012

Y1 - 2012

N2 - Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD.

AB - Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD.

U2 - 10.2147/COPD.S35990

DO - 10.2147/COPD.S35990

M3 - Journal article

C2 - 23055716

VL - 7

SP - 673

EP - 678

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -

ID: 48598189